These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34530804)

  • 41. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
    Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; West DJ;
    Pharmacoepidemiol Drug Saf; 2002; 11(3):189-202. PubMed ID: 12051118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.
    Bardenheier BH; Duderstadt SK; Engler RJ; McNeil MM
    Vaccine; 2016 Aug; 34(37):4406-14. PubMed ID: 27449076
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign.
    Gbenewei E; Nomhwange T; Taiwo L; Ayodeji I; Yusuf K; Jean Baptiste AE; Nsubuga P; Braka F; Oteri J; Shuaib F
    Vaccine; 2021 Nov; 39 Suppl 3():C82-C88. PubMed ID: 33714655
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determinants of COVID-19 vaccine-induced myocarditis.
    Rose J; Hulscher N; McCullough PA
    Ther Adv Drug Saf; 2024; 15():20420986241226566. PubMed ID: 38293564
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.
    Moro PL; Woo EJ; Marquez P; Cano M
    Vaccine; 2020 Aug; 38(37):5923-5926. PubMed ID: 32709434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
    Miller ER; McNeil MM; Moro PL; Duffy J; Su JR
    Vaccine; 2020 Nov; 38(47):7458-7463. PubMed ID: 33039207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Do cognitive styles affect vaccine hesitancy? A dual-process cognitive framework for vaccine hesitancy and the role of risk perceptions.
    Martinelli M; Veltri GA
    Soc Sci Med; 2021 Nov; 289():114403. PubMed ID: 34547544
    [TBL] [Abstract][Full Text] [Related]  

  • 48. COVID-19 vaccination in patients with primary immunodeficiencies: an international survey on patient vaccine hesitancy and self-reported adverse events.
    Pergent M; Haerynck F; Hoste L; Gardulf A
    Front Immunol; 2023; 14():1166198. PubMed ID: 37143673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Age inappropriate influenza vaccination in infants less than 6 months old, 2010-2018.
    Suragh TA; Hibbs B; Marquez P; McNeil MM
    Vaccine; 2020 May; 38(21):3747-3751. PubMed ID: 32273185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Parents' and caregivers' role toward childhood vaccination in Albania: assessment of predictors of vaccine hesitancy.
    Gjini E; Moramarco S; Carestia MC; Cenko F; Ylli A; Mehmeti I; Palombi L; Buonomo E
    Ann Ig; 2023; 35(1):75-83. PubMed ID: 35532052
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Who is unlikely to report adverse events after vaccinations to the Vaccine Adverse Event Reporting System (VAERS)?
    McNeil MM; Li R; Pickering S; Real TM; Smith PJ; Pemberton MR
    Vaccine; 2013 May; 31(24):2673-9. PubMed ID: 23597717
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India.
    Joshi J; Das MK; Polpakara D; Aneja S; Agarwal M; Arora NK
    Indian J Pediatr; 2018 Feb; 85(2):139-148. PubMed ID: 29170922
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety of Second-Dose Single-Antigen Varicella Vaccine.
    Su JR; Leroy Z; Lewis PW; Haber P; Marin M; Leung J; Woo EJ; Shimabukuro TT
    Pediatrics; 2017 Mar; 139(3):. PubMed ID: 28174201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
    Woo EJ; Gee J; Marquez P; Baggs J; Abara WE; McNeil MM; Dimova RB; Su JR
    Vaccine; 2023 Jul; 41(30):4422-4430. PubMed ID: 37321898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. COVID-19 Vaccine Acceptance and Uptake in Bangkok, Thailand: Cross-sectional Online Survey.
    Remmel C; Tuli G; Varrelman TJ; Han AR; Angkab P; Kosiyaporn H; Netrpukdee C; Sorndamrih S; Thamarangsi T; Brownstein JS; Astley CM
    JMIR Public Health Surveill; 2023 Apr; 9():e40186. PubMed ID: 36811852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.
    Niu MT; Ball R; Woo EJ; Burwen DR; Knippen M; Braun MM;
    Vaccine; 2009 Jan; 27(2):290-7. PubMed ID: 18992783
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015-2018.
    Hu R; Peng S; Liu Y; Tang F; Wang Z; Zhang L; Gao J; Guo H
    BMC Public Health; 2021 Jul; 21(1):1338. PubMed ID: 34229643
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety.
    Iskander JK; Miller ER; Chen RT
    Pediatr Ann; 2004 Sep; 33(9):599-606. PubMed ID: 15462575
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety.
    Luo C; Du J; Cuker A; Lautenbach E; Asch DA; Poland GA; Tao C; Chen Y
    Sci Rep; 2022 Jun; 12(1):10946. PubMed ID: 35768434
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.
    Sukumaran L; McNeil MM; Moro PL; Lewis PW; Winiecki SK; Shimabukuro TT
    Clin Infect Dis; 2015 May; 60(10):e58-65. PubMed ID: 25637587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.